Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 13/20 | 0.95 |
| ▸ | KIT known ✓ | P10721 | 5/20 | 0.76 |
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.73 |
| ▸ | BRAF known ✓ | P15056 | 3/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | FLT3 | P36888 | 1/20 | 0.70 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431360 | 0.97 | ABL1 (1.00) | ABL1KITEGFRBRAFFGFR1 | |
| SCHEMBL29515093 | 0.97 | ABL1 (1.00) | ABL1KITEGFRBRAFFGFR1 | |
| SCHEMBL22699303 | 0.89 | ABL1 (0.85) | ABL1KITEGFRBRAFFGFR1 | |
| SCHEMBL22549164 | 0.89 | KIT (0.84) | ABL1KITEGFRBRAFFGFR1 | |
| SCHEMBL24626768 | 0.87 | ABL1 (0.81) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL29675010 | 0.87 | ABL1 (0.81) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL31620735 | 0.86 | KIT (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL4112245 | 0.86 | ABL1 (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL24626028 | 0.86 | ABL1 (0.79) | ABL1KITFGFR1CYP2C9PDGFRA | |
| Olverembatinib SCHEMBL14953403 | 0.86 | ABL1 (0.94) | ABL1KITFGFR1CYP2C9PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3999056-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | claimed |
| EP-3999056-B1 | PHARMACEUTICAL COMBINATION AND ITS USE IN THE PREVENTION AND TREATMENT OF CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2025-07-24 | — | — | US | disclosed |
| US-12233047-B2 | Pharmaceutical combination and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| EP-3999056-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233047-B2 | Pharmaceutical combination and use thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 653/4885KIT 813/4885EGFR 1055/4885 |
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 640/4885KIT 747/4885EGFR 1038/4885 |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 653/4885KIT 813/4885EGFR 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.